BioNotebook: Janssen to open another incubator; venture capital, IPO updates; Ligand/Omthera deal; Chimerix/Merck no deal
This article was originally published in Scrip
Executive Summary
Another Janssen Labs planned for San Francisco; First quarter corporate VC numbers; Crown, Proteon raise venture cash; Marinus, ZS Pharma file for IPOs; Omthera licenses Ligand technology; Merck returns rights to Chimerix drug.